DJIA 18,207.81 75.11 0.41%
NASDAQ 4,985.09 21.56 0.43%
S&P 500 2,109.63 5.13 0.24%
market minute promo

ImmunoGen (NASDAQ: IMGN)

7.65 0.05 (0.66%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

IMGN $7.65 0.66%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $7.58
Previous Close $7.60
Daily Range $7.51 - $7.65
52-Week Range $5.34 - $17.76
Market Cap $658.7M
P/E Ratio -9.05
Dividend (Yield) $0.00 (0.0%)
Volume 39,626
Average Daily Volume 1,652,496
Current FY EPS -$0.67




Drug Makers

ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website:

News & Commentary

In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer

We know chemotherapy kills cancer cells, but it's also an indiscriminate killer of healthy cells. According to a new study released this past week, an entirely new treatment pathway could eliminate a significant portion of healthy cell death.

Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval

5 Analyst Stock Picks Under $10 With Massive Upside Projections

Here's Why Oppenheimer Upgraded ImmunoGen To Outperform

Why ImmunoGen, Inc. Shares Rocketed Higher By 25% in January

ImmunoGen stock roars higher based on perhaps the most unlikely of sources: it's second-quarter earnings report. Find out what has Wall Street and investors so excited.

Stock To Watch: Immunogen (IMGN) In Perilous Reversal

Benzinga's Top #PreMarket Losers

Gulf Resources (GURE) Soars on Natural Gas Discovery, ImmunoGen (IMGN) and Synaptics (SYNA) ...

Update: ImmunoGen Earnings

ImmunoGen Shares Surge 30% Following Earnings

See More IMGN News...

IMGN's Top Competitors

IMGN $7.65 (0.66%)
Current stock: IMGN
AMGN $158.32 (0.38%)
Current stock: AMGN
GILD $102.86 (-0.65%)
Current stock: GILD
BIIB $407.00 (-0.63%)
Current stock: BIIB